vs
Indivior Pharmaceuticals, Inc.（INDV）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Indivior Pharmaceuticals, Inc.的季度营收约是Rapid7, Inc.的1.6倍（$357.0M vs $217.4M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs 1.4%，领先27.4%），Rapid7, Inc.自由现金流更多（$36.4M vs $-245.0M）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
INDV vs RPD — 直观对比
营收规模更大
INDV
是对方的1.6倍
$217.4M
净利率更高
INDV
高出27.4%
1.4%
自由现金流更多
RPD
多$281.4M
$-245.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $217.4M |
| 净利润 | $103.0M | $3.1M |
| 毛利率 | 82.1% | 68.9% |
| 营业利润率 | 22.7% | 1.0% |
| 净利率 | 28.9% | 1.4% |
| 营收同比 | — | 0.5% |
| 净利润同比 | 390.5% | 44.1% |
| 每股收益（稀释后） | $0.79 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVRPD
| Q4 25 | $357.0M | $217.4M | ||
| Q3 25 | $314.0M | $218.0M | ||
| Q2 25 | $302.0M | $214.2M | ||
| Q1 25 | $266.0M | $210.3M | ||
| Q4 24 | — | $216.3M | ||
| Q3 24 | $307.0M | $214.7M | ||
| Q2 24 | $299.0M | $208.0M | ||
| Q1 24 | — | $205.1M |
净利润INDVRPD
| Q4 25 | $103.0M | $3.1M | ||
| Q3 25 | $42.0M | $9.8M | ||
| Q2 25 | $18.0M | $8.3M | ||
| Q1 25 | $47.0M | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $22.0M | $15.4M | ||
| Q2 24 | $-97.0M | $6.5M | ||
| Q1 24 | — | $1.4M |
毛利率INDVRPD
| Q4 25 | 82.1% | 68.9% | ||
| Q3 25 | 73.2% | 70.2% | ||
| Q2 25 | 82.8% | 70.6% | ||
| Q1 25 | 83.1% | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | 78.5% | 70.6% | ||
| Q2 24 | 73.6% | 70.7% | ||
| Q1 24 | — | 70.3% |
营业利润率INDVRPD
| Q4 25 | 22.7% | 1.0% | ||
| Q3 25 | 13.7% | 2.7% | ||
| Q2 25 | 23.8% | 1.6% | ||
| Q1 25 | 24.8% | -0.0% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 11.4% | 6.0% | ||
| Q2 24 | -39.5% | 2.5% | ||
| Q1 24 | — | 4.7% |
净利率INDVRPD
| Q4 25 | 28.9% | 1.4% | ||
| Q3 25 | 13.4% | 4.5% | ||
| Q2 25 | 6.0% | 3.9% | ||
| Q1 25 | 17.7% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 7.2% | 7.2% | ||
| Q2 24 | -32.4% | 3.1% | ||
| Q1 24 | — | 0.7% |
每股收益（稀释后）INDVRPD
| Q4 25 | $0.79 | $0.05 | ||
| Q3 25 | $0.33 | $0.15 | ||
| Q2 25 | $0.14 | $0.13 | ||
| Q1 25 | $0.38 | $0.03 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $0.16 | $0.21 | ||
| Q2 24 | $-0.72 | $0.09 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-98.0M | $154.7M |
| 总资产 | $1.2B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INDVRPD
| Q4 25 | $195.0M | $474.7M | ||
| Q3 25 | $445.0M | $407.1M | ||
| Q2 25 | $510.0M | $511.7M | ||
| Q1 25 | $373.0M | $493.5M | ||
| Q4 24 | — | $521.7M | ||
| Q3 24 | — | $443.7M | ||
| Q2 24 | — | $442.6M | ||
| Q1 24 | — | $411.7M |
股东权益INDVRPD
| Q4 25 | $-98.0M | $154.7M | ||
| Q3 25 | $-207.0M | $127.2M | ||
| Q2 25 | $-257.0M | $90.4M | ||
| Q1 25 | $-285.0M | $52.7M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $-310.0M | $-5.1M | ||
| Q2 24 | $-281.0M | $-52.6M | ||
| Q1 24 | — | $-86.4M |
总资产INDVRPD
| Q4 25 | $1.2B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | $36.4M |
| 自由现金流率自由现金流/营收 | -68.6% | 16.8% |
| 资本支出强度资本支出/营收 | 6.7% | 0.5% |
| 现金转化率经营现金流/净利润 | -2.15× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $-93.0M | $146.2M |
8季度趋势，按日历期对齐
经营现金流INDVRPD
| Q4 25 | $-221.0M | $37.6M | ||
| Q3 25 | $-39.0M | $39.0M | ||
| Q2 25 | $158.0M | $47.5M | ||
| Q1 25 | $75.0M | $29.8M | ||
| Q4 24 | — | $63.8M | ||
| Q3 24 | $2.0M | $44.0M | ||
| Q2 24 | $88.0M | $32.9M | ||
| Q1 24 | — | $31.1M |
自由现金流INDVRPD
| Q4 25 | $-245.0M | $36.4M | ||
| Q3 25 | $-59.0M | $34.8M | ||
| Q2 25 | $141.0M | $46.6M | ||
| Q1 25 | $70.0M | $28.4M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | $-5.0M | $42.6M | ||
| Q2 24 | $84.0M | $32.6M | ||
| Q1 24 | — | $30.4M |
自由现金流率INDVRPD
| Q4 25 | -68.6% | 16.8% | ||
| Q3 25 | -18.8% | 16.0% | ||
| Q2 25 | 46.7% | 21.8% | ||
| Q1 25 | 26.3% | 13.5% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | -1.6% | 19.9% | ||
| Q2 24 | 28.1% | 15.7% | ||
| Q1 24 | — | 14.8% |
资本支出强度INDVRPD
| Q4 25 | 6.7% | 0.5% | ||
| Q3 25 | 6.4% | 1.9% | ||
| Q2 25 | 5.6% | 0.4% | ||
| Q1 25 | 1.9% | 0.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 2.3% | 0.6% | ||
| Q2 24 | 1.3% | 0.1% | ||
| Q1 24 | — | 0.3% |
现金转化率INDVRPD
| Q4 25 | -2.15× | 12.01× | ||
| Q3 25 | -0.93× | 3.97× | ||
| Q2 25 | 8.78× | 5.70× | ||
| Q1 25 | 1.60× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 0.09× | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
